Bağırsak hastalıkları ve bağırsakla ilişkili hastalıkların ön tanısı için biyosensör ve sensör sistemleri geliştirilmesi
Proje no. 21017 · Durum: Kapanmış · 2019
Özet
Inflammatory bowel diseases (IBD) are a group of inflammatory diseases of the gastrointestinal tract (GIS) for which there is no known cure, with a chronic course, characterized by periods of remission and exacerbation. IBD can manifest in different ways in genetically predisposed individuals, it can be very painful and devastating, and sometimes life-threatening. IBD is divided into two groups as Ulcerative colitis (UC) and Crohn's Disease (CH). UK and CH can cause inflammation anywhere in the digestive tract. Apart from these intestinal diseases, it is noteworthy that there are also chronic diseases associated with intestinal inflammation. Today, great progress has been made in the diagnosis, treatment and post-treatment monitoring of diseases. In the light of these developments, it is obvious that diagnosis, treatment and post-treatment monitoring processes are interrelated. In this project application, we aim to develop this project, which deals with all these processes of diseases, especially the diagnosis part, namely the beginning part. Accordingly, our main goal is to develop a low-cost, fast, accurate and effective diagnosis system, to reduce health expenditures, to reduce foreign dependency, and to take measures to prevent future diseases. Considering the findings, the biosensor system was modified with the target immobilization method and made suitable for the determination of the S100A8-9 biomarker. A biosensor was developed with the aptamer immobilized on the gold nanoparticle by the interaction of cystamine and avidin biotin. Although the marker molecule on the aptamer undergoes transformation at high potential, its electrochemical potential decreased with S100A8-9 binding as a result of conformational changes. This is evident from the LSV results. The biosensor provides measurement in the range of 20-800 ug/g. This shows that it is more sensitive than the commercially used LFA. When interpreted in terms of method comparison, the biosensor can give as accurate results as LFA. LOD and LOQ values are correlated with the standard graph, making it a very suitable biosensor. The measurement time was determined as 900 seconds with chronoimpedimetric measurement. It is also possible to measure at lower times in this way, but this time is sufficient for a meaningful signal in experimental development. Affinity-based binding and the affinity of the aptamer determine this time. From the point of view of selectivity, it is promising for the future of the study that it gives very low signals against S100A8 and 9, which are the states of dimerization. In conclusion, the aptamer-based calprotectin biosensor is very suitable for measuring this biomarker used in Crohn's disease.